190 related articles for article (PubMed ID: 22192846)
21. A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever.
Cartee RT; Thanawastien A; Griffin Iv TJ; Mekalanos JJ; Bart S; Killeen KP
PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007912. PubMed ID: 31905228
[TBL] [Abstract][Full Text] [Related]
22. Vi polysaccharide-protein conjugate vaccine for the prevention of typhoid fever in children: hope or hype?
Pulickal AS; Pollard AJ
Expert Rev Vaccines; 2007 Jun; 6(3):293-5. PubMed ID: 17542742
[No Abstract] [Full Text] [Related]
23. Preparation and testing of a Vi conjugate vaccine using pneumococcal surface protein A (PspA) from Streptococcus pneumoniae as the carrier protein.
Kothari N; Genschmer KR; Kothari S; Kim JA; Briles DE; Rhee DK; Carbis R
Vaccine; 2014 Sep; 32(43):5755-60. PubMed ID: 25171842
[TBL] [Abstract][Full Text] [Related]
24. [Experimental study of controlled release microencapsulated Salmonella typhi capsular polysaccharide vaccines immunized mice].
Yang C; Yan R; Zeng W; Zhang Y; Jia W; Liu J; Zhou S; Li X; Deng X
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2003 Dec; 20(4):626-9. PubMed ID: 14716862
[TBL] [Abstract][Full Text] [Related]
25. Comparison of anti-Vi IgG responses between two clinical studies of typhoid Vi conjugate vaccines (Vi-DT vs Vi-TT).
Lee EY; Park JY; Kim DR; Song M; Sahastrabuddhe S; Kim H; Chon Y; Yang JS
PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008171. PubMed ID: 32203521
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and immunogenicity evaluation of Salmonella enterica serovar Paratyphi A O-specific polysaccharide conjugated to diphtheria toxoid.
Ali A; An SJ; Cui C; Haque A; Carbis R
Hum Vaccin Immunother; 2014; 10(6):1494-8. PubMed ID: 24603090
[TBL] [Abstract][Full Text] [Related]
27. In vitro characterization and preclinical immunogenicity of Typhax, a typhoid fever protein capsular matrix vaccine candidate.
Griffin TJ; Thanawastien A; Cartee RT; Mekalanos JJ; Killeen KP
Hum Vaccin Immunother; 2019; 15(6):1310-1316. PubMed ID: 31021700
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of two WHO First International Standards for Vi polysaccharide from Citrobacter freundii and Salmonella enterica subspecies enterica serovar Typhi.
Gao F; Swann C; Rigsby P; Rijpkema S; Lockyer K; Logan A; Bolgiano B;
Biologicals; 2019 Jan; 57():34-45. PubMed ID: 30502020
[TBL] [Abstract][Full Text] [Related]
29. Gamma 3 gene-disrupted mice selectively deficient in the dominant IgG subclass made to bacterial polysaccharides undergo normal isotype switching after immunization with polysaccharide-protein conjugate vaccines.
Shapiro DA; Threadgill DS; Copfer MJ; Corey DA; McCool TL; McCormick LL; Magnuson TR; Greenspan NS; Schreiber JR
J Immunol; 1998 Oct; 161(7):3393-9. PubMed ID: 9759856
[TBL] [Abstract][Full Text] [Related]
30. Revaccination with locally-produced vi typhoid polysaccharide vaccine among chinese school-aged children: safety and immunogenicity findings.
Zhou WZ; Koo HW; Wang XY; Zhang J; Park JK; Zhu F; Deen J; Acosta CJ; Chen Y; Wang H; Galindo CM; Ochiai L; Park T; von Seidlein L; Xu ZY; Clemens JD
Pediatr Infect Dis J; 2007 Nov; 26(11):1001-5. PubMed ID: 17984806
[TBL] [Abstract][Full Text] [Related]
31. Isotype concentrations of human antibodies to Haemophilus influenzae type b polysaccharide (Hib) in young adults immunized with the polysaccharide as such or conjugated to a protein (diphtheria toxoid).
Mäkelä O; Mattila P; Rautonen N; Seppälä I; Eskola J; Käyhty H
J Immunol; 1987 Sep; 139(6):1999-2004. PubMed ID: 3497985
[TBL] [Abstract][Full Text] [Related]
32. Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG.
Rijpkema S; Hockley J; Logan A; Rigsby P; Atkinson E; Jin C; Goldblatt D; Liang H; Bachtiar NS; Yang JS; Goel A; Ramasamy V; Pasetti MF; Pollard AJ;
Biologicals; 2018 Nov; 56():29-38. PubMed ID: 30201529
[TBL] [Abstract][Full Text] [Related]
33. Modulation of immune response and enhanced clearance of Salmonella typhi by delivery of Vi polysaccharide conjugate using PLA nanoparticles.
Meena J; Kumar R; Singh M; Ahmed A; Panda AK
Eur J Pharm Biopharm; 2020 Jul; 152():270-281. PubMed ID: 32470636
[TBL] [Abstract][Full Text] [Related]
34. Development of a bead immunoassay to measure Vi polysaccharide-specific serum IgG after vaccination with the Salmonella enterica serovar Typhi Vi polysaccharide.
Staats HF; Kirwan SM; Whisnant CC; Stephenson JL; Wagener DK; Majumder PP
Clin Vaccine Immunol; 2010 Mar; 17(3):412-9. PubMed ID: 20107010
[TBL] [Abstract][Full Text] [Related]
35. Carrier priming with CRM 197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: biophysical and immunochemical interpretation.
Pecetta S; Lo Surdo P; Tontini M; Proietti D; Zambonelli C; Bottomley MJ; Biagini M; Berti F; Costantino P; Romano MR;
Vaccine; 2015 Jan; 33(2):314-20. PubMed ID: 25448110
[TBL] [Abstract][Full Text] [Related]
36. Nasal immunization of mice with AFCo1 or AFPL1 plus capsular polysaccharide Vi from Salmonella typhi induces cellular response and memory B and T cell responses.
Romeu B; Lastre M; Reyes L; González E; Borrero Y; Lescaille D; Pérez R; Nuñez D; Pérez O
Vaccine; 2014 Dec; 32(51):6971-6978. PubMed ID: 25454865
[TBL] [Abstract][Full Text] [Related]
37. The influence of conjugation variables on the design and immunogenicity of a glycoconjugate vaccine against Salmonella Typhi.
Arcuri M; Di Benedetto R; Cunningham AF; Saul A; MacLennan CA; Micoli F
PLoS One; 2017; 12(12):e0189100. PubMed ID: 29287062
[TBL] [Abstract][Full Text] [Related]
38. First characterization of immunogenic conjugates of Vi negative Salmonella Typhi O-specific polysaccharides with rEPA protein for vaccine development.
Salman M; St Michael F; Ali A; Jabbar A; Cairns C; Hayes AC; Rahman M; Iqbal M; Haque A; Cox AD
J Immunol Methods; 2017 Nov; 450():27-33. PubMed ID: 28735760
[TBL] [Abstract][Full Text] [Related]
39. Development of a guinea-pig model for potency/immunogenicity evaluation of diphtheria, tetanus acellular pertussis (DTaP) and Haemophilus influenzae type b polysaccharide conjugate vaccines.
Gupta RK; Anderson R; Cecchini D; Rost B; Griffin P; Benscoter K; Xu J; Montanez-Ortiz L; Siber GR
Dev Biol Stand; 1996; 86():283-96. PubMed ID: 8785957
[TBL] [Abstract][Full Text] [Related]
40. Protective efficacy and immunogenicity of Vi-porin conjugate against Salmonella typhi.
Singh M; Ganguly NK; Kumar L; Vohra H
Microbiol Immunol; 1999; 43(6):535-42. PubMed ID: 10480549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
